Hepatocellular carcinoma (hcc) is the 4th most common cause of cancer-related deaths worldwide1. The coexistence of hcc and liver cirrhosis often poses a unique challenge in identifying the optimal treatment approach in the context of preserving hepatic function. As a consequence, multidisciplinary care has been the cornerstone of hcc management—considering liver morphology and function, tumour biology, and the patient’s status. With insights from internationally recognized guest contributors, this special Current Oncology supplement highlights the current state of the art in the clinical management of hcc, recognizing the rapidly changing landscape of treatment options.
展开▼
